NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company dedicated to developing novel, oral, non-statin medicines for patients with metabolic diseases, particularly those at high risk of cardiovascular disease (CVD). The company's primary focus is on addressing the unmet medical needs of patients with elevated low-density lipoprotein cholesterol (LDL-C) for whom existing therapies are either insufficiently effective or poorly tolerated.
The core of NewAmsterdam's business model revolves around the clinical development and future commercialization of its lead product candidate, obicetrapib. Obicetrapib is a highly selective, next-generation, oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor. It is currently being evaluated in multiple Phase 3 clinical trials, both as a monotherapy and as a fixed-dose combination with ezetimibe, to assess its efficacy in lowering LDL-C and reducing major adverse cardiovascular events (MACE). Beyond cardiovascular applications, the company is also exploring obicetrapib's potential in treating Alzheimer's disease through early-stage clinical trials.
As a clinical-stage company, NewAmsterdam Pharma does not currently generate revenue from commercial product sales. Its operations are funded through capital markets, strategic partnerships, and licensing agreements. Notably, the company signed a significant licensing deal with the Menarini Group to commercialize obicetrapib in Europe, which provided substantial upfront capital and potential future milestone payments. Headquartered in the Netherlands, NewAmsterdam operates globally, conducting extensive clinical trials across various regions to support its regulatory submissions and future commercial launches in the United States, Europe, and other key markets.
